FINWIRES · TerminalLIVE
FINWIRES

D-Wave Gains Commercial Traction, Wedbush Says

By

D-Wave Quantum (QBTS) is expected to report only slightly better Q2 revenue than Q1 than missed market expectations, but the firm points to a significant ramp in H2, Wedbush said in a note Wednesday.

Bookings of $33.4 million and remaining performance obligations of $42.4 million were the most important figures in the quarter because they point to future revenue, the report said.

The note said near-term earnings results have minimal meaning for D-Wave, an early stage quantum computer company.

"We continue to view technological progress (on both annealing and gate-model platforms) and bookings momentum as the most important leading indicators of the company's progress," the report said.

The note also pointed to its investor Day on June 1 as likely a signal that any updates will skew positive.

Wedbush kept its outperform rating and $40 price target.

Price: $21.27, Change: $-1.09, Percent Change: -4.85%

What else is happening in Wire?

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP